176 related articles for article (PubMed ID: 27734578)
21. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
22. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
23. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
[TBL] [Abstract][Full Text] [Related]
24. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors.
Masciangelo R; Bosisio C; Donnez J; Amorim CA; Dolmans MM
Hum Reprod; 2018 Feb; 33(2):212-219. PubMed ID: 29281007
[TBL] [Abstract][Full Text] [Related]
25. New splicing variants for human Tyrosine Hydroxylase gene with possible implications for the detection of minimal residual disease in patients with neuroblastoma.
Parareda A; Villaescusa JC; Sanchez de Toledo J; Gallego S
Neurosci Lett; 2003 Jan; 336(1):29-32. PubMed ID: 12493595
[TBL] [Abstract][Full Text] [Related]
26. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
[TBL] [Abstract][Full Text] [Related]
27. PHOX2B Is Associated with Neuroblastoma Cell Differentiation.
Yang L; Ke XX; Xuan F; Tan J; Hou J; Wang M; Cui H; Zhang Y
Cancer Biother Radiopharm; 2016 Mar; 31(2):44-51. PubMed ID: 26910576
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients.
Avigad S; Feinberg-Gorenshtein G; Luria D; Jeison M; Stein J; Grunshpan A; Sverdlov Y; Ash S; Yaniv I
J Pediatr Hematol Oncol; 2009 Jan; 31(1):22-6. PubMed ID: 19125082
[TBL] [Abstract][Full Text] [Related]
29. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.
Thwin KKM; Ishida T; Uemura S; Yamamoto N; Lin KS; Tamura A; Kozaki A; Saito A; Kishimoto K; Mori T; Hasegawa D; Kosaka Y; Nino N; Takafuji S; Iijima K; Nishimura N
J Mol Diagn; 2020 Feb; 22(2):236-246. PubMed ID: 31837427
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
Shono K; Tajiri T; Fujii Y; Suita S
J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a human ovarian follicle isolation technique to obtain disease-free follicle suspensions before safely grafting to cancer patients.
Soares M; Sahrari K; Amorim CA; Saussoy P; Donnez J; Dolmans MM
Fertil Steril; 2015 Sep; 104(3):672-80.e2. PubMed ID: 26095134
[TBL] [Abstract][Full Text] [Related]
32. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
[TBL] [Abstract][Full Text] [Related]
34. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel pathways and molecules able to down-regulate PHOX2B gene expression by in vitro drug screening approaches in neuroblastoma cells.
Di Zanni E; Fornasari D; Ravazzolo R; Ceccherini I; Bachetti T
Exp Cell Res; 2015 Aug; 336(1):43-57. PubMed ID: 25882494
[TBL] [Abstract][Full Text] [Related]
36. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
[TBL] [Abstract][Full Text] [Related]
37. Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis.
Imbert R; Moffa F; Tsepelidis S; Simon P; Delbaere A; Devreker F; Dechene J; Ferster A; Veys I; Fastrez M; Englert Y; Demeestere I
Hum Reprod; 2014 Sep; 29(9):1931-40. PubMed ID: 24958067
[TBL] [Abstract][Full Text] [Related]
38. Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma.
de Pontual L; Trochet D; Bourdeaut F; Thomas S; Etchevers H; Chompret A; Minard V; Valteau D; Brugieres L; Munnich A; Delattre O; Lyonnet S; Janoueix-Lerosey I; Amiel J
Eur J Cancer; 2007 Nov; 43(16):2366-72. PubMed ID: 17765533
[TBL] [Abstract][Full Text] [Related]
39. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
40. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
